Fortgeschrittenes SCLC: PD-1-Antikörper als mögliche Therapiealternative
Crossref DOI link: https://doi.org/10.1007/s15004-022-9149-5
Published Online: 2022-07-28
Published Print: 2022-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kempe, Sabrina
Text and Data Mining valid from 2022-07-28
Version of Record valid from 2022-07-28
Article History
First Online: 28 July 2022
Free to read: This content has been made available to all.